ImmunoPrecise Antibodies Ltd. (IPA)
- ACCESSWIRE
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TM Platform. LENSai, which is ...
- ACCESSWIRE
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
VICTORIA, BC / ACCESSWIRE/ April 12, 2024 / InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability and speed challenges partnered with ImmunoPrecise Antibodies (NASDAQ:IPA) ...
- Business Wire
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
VICTORIA, British Columbia, March 28, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce a landmark collaboration. This collaboration int
